Among COVID-19 convalescent subjects, 5/8 (63%) HIV-1-uninfected and 9/13 (69%) HIV-1-infected subjects had detectable anti-spike IgA in saliva, whereas 0/8 (0%) HIV-1-uninfected and 1/13 (8%) HIV-1-infected subjects had detectable anti-spike IgG in saliva. This evidence concerns the gene CD79A and COVID-19.